Importance of Mesoporous Silica Particle Size in the Stabilization of Amorphous Pharmaceuticals-The Case of Simvastatin.
Simvastatin
amorphous pharmaceuticals
mesoporous silica
recrystallization
stabilization
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
22 Apr 2020
22 Apr 2020
Historique:
received:
27
03
2020
revised:
12
04
2020
accepted:
14
04
2020
entrez:
26
4
2020
pubmed:
26
4
2020
medline:
26
4
2020
Statut:
epublish
Résumé
In this paper, the role of mesoporous silica (MS) particle size in the stabilization of amorphous simvastatin (SVT) is revealed. For inhibiting recrystallization of the supercooled drug, the two MS materials (Syloid
Identifiants
pubmed: 32331310
pii: pharmaceutics12040384
doi: 10.3390/pharmaceutics12040384
pmc: PMC7238159
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Narodowym Centrum Nauki
ID : 2015/16/W/NZ7/00404 (SYMFONIA 3)
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Pharm Res. 2018 Jan 5;35(1):25
pubmed: 29305717
Drug Dev Ind Pharm. 2019 Mar;45(3):349-358
pubmed: 30411991
Phys Rev Lett. 2016 Jan 15;116(2):025702
pubmed: 26824551
Mol Pharm. 2016 Apr 4;13(4):1308-16
pubmed: 26981876
Mol Pharm. 2017 Oct 2;14(10):3370-3380
pubmed: 28787567
Eur J Pharm Biopharm. 2016 Nov;108:220-225
pubmed: 27648957
Acta Pharm Sin B. 2015 Sep;5(5):442-53
pubmed: 26579474
Int J Pharm X. 2019 Jul 22;1:100026
pubmed: 31517291
Int J Pharm. 2018 Jun 10;544(1):153-157
pubmed: 29679750
Adv Mater. 2017 Mar;29(9):
pubmed: 28084658
Pharmacol Rev. 2013 Jan;65(1):315-499
pubmed: 23383426
J Pharm Sci. 2012 Nov;101(11):4220-30
pubmed: 22930424
Mol Pharm. 2006 Nov-Dec;3(6):631-43
pubmed: 17140251
Pharm Res. 2010 Dec;27(12):2704-14
pubmed: 20859662
Mol Pharm. 2013 Jun 3;10(6):2270-82
pubmed: 23594226
Nanomedicine (Lond). 2014 Dec;9(18):2745-59
pubmed: 24938439
Int J Pharm. 2014 Jan 30;461(1-2):459-68
pubmed: 24368106
Chem Commun (Camb). 2007 Apr 7;(13):1375-7
pubmed: 17377687
Drug Dev Ind Pharm. 2003 Aug;29(7):739-44
pubmed: 12906331
Adv Drug Deliv Rev. 2012 May 1;64(6):480-95
pubmed: 22265844
Int J Pharm X. 2019 Feb 22;1:100008
pubmed: 31517273
Expert Opin Drug Deliv. 2007 Jul;4(4):403-16
pubmed: 17683253
Adv Drug Deliv Rev. 2012 Apr;64(5):396-421
pubmed: 21843564
Mol Pharm. 2017 Apr 3;14(4):1154-1168
pubmed: 28241116
Int J Pharm. 2018 May 5;542(1-2):186-195
pubmed: 29510175
Mol Pharm. 2014 Nov 3;11(11):4280-90
pubmed: 25310722
J Pharm Sci. 2015 Jan;104(1):276-9
pubmed: 25382848
Mol Pharm. 2018 Jun 4;15(6):2455-2465
pubmed: 29738666
Int J Pharm. 2018 Jan 30;536(1):178-186
pubmed: 29183856
Mol Pharm. 2016 Jun 6;13(6):1937-46
pubmed: 27149568
Mol Pharm. 2012 Apr 2;9(4):894-904
pubmed: 22384922
Mol Pharm. 2015 Feb 2;12(2):484-95
pubmed: 25495614
Mol Pharm. 2017 Aug 7;14(8):2670-2680
pubmed: 28692796
Mol Pharm. 2018 May 7;15(5):1928-1940
pubmed: 29584436
J Pharm Sci. 2018 Jan;107(1):149-155
pubmed: 28603020
Mol Pharm. 2012 Jun 4;9(6):1748-63
pubmed: 22540343
J Phys Chem B. 2010 Oct 14;114(40):12792-801
pubmed: 20849135
Mol Pharm. 2015 Oct 5;12(10):3610-9
pubmed: 26301858
Int J Pharm. 2013 Aug 30;453(1):65-79
pubmed: 22569230
Eur J Pharm Sci. 2020 Jan 1;141:105083
pubmed: 31634557
Adv Drug Deliv Rev. 2016 May 1;100:158-82
pubmed: 26705851
Mol Pharm. 2017 Jan 3;14(1):157-171
pubmed: 28043133
Mol Pharm. 2019 Aug 5;16(8):3626-3635
pubmed: 31287704
Int J Pharm. 2020 Mar 30;578:119099
pubmed: 32006624
Acta Pharm Sin B. 2019 Jan;9(1):19-35
pubmed: 30766775
Pharm Res. 2006 Oct;23(10):2317-25
pubmed: 16927179
J Phys Chem B. 2015 Apr 9;119(14):4873-80
pubmed: 25781503
Int J Pharm. 2013 Nov 18;456(2):301-6
pubmed: 24012867
Mol Pharm. 2014 Jun 2;11(6):1835-43
pubmed: 24731254
J Pharm Sci. 1994 Dec;83(12):1700-5
pubmed: 7891297
J Phys Chem B. 2019 Jun 13;123(23):4996-5003
pubmed: 31120753
Phys Chem Chem Phys. 2017 Apr 12;19(15):9879-9888
pubmed: 28357419
Langmuir. 2007 Apr 24;23(9):5148-53
pubmed: 17397203
Mol Pharm. 2011 Jun 6;8(3):814-22
pubmed: 21534589